The Subcutaneous Drug Development & Delivery Consortium, Inc. has notified the Attorney General and the Federal Trade Commission about changes in its membership as required by law. New members of this research venture include Janssen Research & Development, LLC, Novo Nordisk from Denmark, and Ypsomed AG from Switzerland. This action is part of the ongoing compliance with the National Cooperative Research and Production Act, which limits the damages that antitrust plaintiffs can recover in certain circumstances. The Consortium plans to keep the membership open and continues to update the authorities on its developments.
Simple Explanation
The Subcutaneous Drug Development & Delivery Consortium has added three new members to its team and told the government about it, just like they are supposed to do, to keep everything fair and honest.